A novel low-intensity focused ultrasound (LIFU) activated piezoelectric gel bandage has been developed to address two major challenges in diabetic foot ulcers delayed wound healing and neuropathic pain. Designed to function as an artificial “smart skin,” this self-powered bandage not only protects the wound from the external environment but also acts as a localized therapeutic platform. When activated by low-intensity ultrasound, the gel releases nitric oxide to promote beneficial immune responses, generates mild piezoelectric currents that help reduce pain by modulating sensory nerve activity, and produces reactive oxygen species that aid in controlling microbial infection. This multimodal approach targets both inflammation and nerve hypersensitivity, two key factors that hinder healing in diabetic wounds.

Preclinical findings demonstrated that the technology enhanced tissue repair by improving macrophage polarization toward a pro-healing phenotype while simultaneously stimulating the release of neuropeptides that strengthen protective skin immunity. The combined immune modulation and pain-relief effects contributed to faster wound closure and improved local tissue regeneration. By integrating on-demand drug release, antimicrobial action, and neuromodulation into a single dressing, this ultrasound-activated bandage represents a promising strategy for managing chronic diabetic wounds. The platform may also have broader applications in other non-healing tissue injuries, offering a potential next-generation solution for regenerative wound care.